6th Call for Projects: 2 New Selected Projects
The sixth call for projects opened in November 2013 to finance research with potential therapeutic benefit in sporadic ALS on the following themes:
Biological markers, pathological pathways and mechanisms, therapeutic strategies, innovative molecules in the fields of ALS and protection of motor neurons.
Submission of clinical or patient centric/oriented research projects is particularly encouraged
The Thierry Latran Foundation is extremely grateful for the excellent work done by
the Scientific Advisory Board
Pr Wim Robberecht (Leuven University, Belgium) (President)
Pr Caterina Bendotti (Mario Negri Institute, Milano, Italy)
Dr Séverine Boillée (ICM, Paris, France)
Dr Jan Egebjerg (Lundbeck, Denmark)
Pr Linda Greensmith (University College of London, UK)
Pr Eva Hedlund (Karolinska Institute, Stockholm, Sweden)
Pr Albert Ludolph (Ulm University, Germany)
Pr Leonard H van den Berg (Utrecht University, The Netherland)
and by Elke Boagert, SAB secretary (PHD in Neurosciences, Leuven) who drove the process.
Selection Process :
By December 2013, 19th, deadline for abstract submission, we received
82 abstracts coming from 14 different countries
Since inception, 454 projects were submitted to the Foundation.
Each Member of the Scientific Advisory Board (SAB), assessed independently the 82 abstracts taking into account their scientific quality and their relevance to the objectives of the Foundation. During the process, the members of the Scientific Committee with a conflict of interest did participate neither to assessment nor to discussion.
These assessments have been consolidated and anonymized. A meeting of the Scientific Committee was held in February 2014 for selection, validated by the Foundation. 17projects were selected for full application.
Each of the 17 application was analyzed by 2 different ‘referees’, specialized on the theme of the project and having no connection with the applicants. The members of the Scientific Committee met in May to assess the projects on the basis of the opinion of the “referees” and to classify them into 3 groups A (strong recommendation for funding) B (projects recommended to be financed according to the available budget) and C (projects not recommended for funding). The SAB’s recommendations were presented to the Executive Committee in June 2014.
At the end, two projects were selected, meeting the selection criteria i.e. scientific excellence and contribution to the development of a therapy.1. Project hnRNP proteins in ALS
Bettina Schmid (Munich, Germany)
Duration : 24 months
Grant : 150 000 €
2. Project OptiMus
Barney Bryson (London, UK)
Duration : 24 months
Grant : 160 000 €
This project is also financed by the Motor Neuron Disease Association